Cabergoline dosage for treating prolactinoma

Cabergoline has become the internationally recommended first-choice drug in the treatment of hyperprolactinemia (HPRL) and prolactinoma. Its reasonable dosage is crucial for efficacy and safety. Unlike traditional bromocriptine, which requires frequent administration, cabergoline, with its long-acting properties, can achieve the purpose of continuously suppressing prolactin secretion with less frequent administration.

In the treatment of prolactinoma, cabergoline is usually started at a lower dose and is taken orally once or twice weekly. The common initial dose is mostly 0.25 to 0.5 mg per week. Doctors will gradually adjust the dose based on the patient's serum prolactin level and tumor shrinkage. In some patients, the dose may be gradually increased to 1 mg to 2 mg per week to maintain desired efficacy. It needs to be emphasized that dosage adjustment must follow the principle of individualization, not only to ensure that prolactin levels are effectively controlled, but also to avoid unnecessary side effects caused by overdose.

Long-term follow-up shows that after receiving cabergoline treatment, the vast majority of patients with prolactinoma can return their serum prolactin levels to the normal range, significantly reduce the tumor size, and some patients even experience complete tumor regression. This significant efficacy is closely related to the maintenance of reasonable dosage.

In addition, doctors usually recommend regular monitoring of prolactin levels and imaging changes during treatment so that dosage can be adjusted in a timely manner. For patients with lower body weight or drug-sensitive patients, the maintenance dose may be lower, while for patients with larger macroadenoma, a relatively higher dose may be required to achieve the desired effect.

In general, the dosage design of cabergoline takes into account both efficacy and safety. By taking the medication regularly once or twice a week, the vast majority of patients can achieve stable and lasting disease control. Cabergoline undoubtedly improves patient compliance and quality of life compared to traditional medications that require daily medication.

Reference materials:https://www.drugs.com/mtm/cabergoline.html